PT-141 Palatin.
Palatin, under license from Competitive Technology, is developing the peptide PT-141, a synthetically modified analog of PT-14, as a nasal spray for the potential treatment of erectile dysfunction (ED) and female sexual dysfunction. In September 2003, Palatin had completed a phase IIb trial in patients with ED and in February 2004, Palatin planned to start phase III trials in early 2005.
Hedlund
Petter
P
Department of Clinical Pharmacology, University of Lund, F-blocket, Universitetssjukhuset, 22185 Lund, Sweden. petter.hedlund@klinfarm.lu.se
D000818:Animals; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D007172:Erectile Dysfunction / Q000188:drug therapy; D006801:Humans; D008297:Male; D010456:Peptides, Cyclic / Q000737:chemistry* / Q000494:pharmacology / Q000627:therapeutic use; D044101:Receptors, Melanocortin / Q000819:agonists; D013329:Structure-Activity Relationship; D000521:alpha-MSH
D010456:Peptides, Cyclic; D044101:Receptors, Melanocortin; D000521:alpha-MSH; C476721:bremelanotide